Cargando…

Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis

Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Wen, Chi, Hao, Tang, Hua, Xu, Jianjun, Wang, Jing, Cai, Wan, Ma, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660608/
https://www.ncbi.nlm.nih.gov/pubmed/34788230
http://dx.doi.org/10.18632/aging.203576
_version_ 1784613223955169280
author Ge, Wen
Chi, Hao
Tang, Hua
Xu, Jianjun
Wang, Jing
Cai, Wan
Ma, Haitao
author_facet Ge, Wen
Chi, Hao
Tang, Hua
Xu, Jianjun
Wang, Jing
Cai, Wan
Ma, Haitao
author_sort Ge, Wen
collection PubMed
description Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer cell malignant transformation. The murine subcutaneous tumor model was used to assess the tumorigenesis of NSCLC in vivo. The assays of circRNA precipitation, RNA immunoprecipitation, and luciferase reporter were performed to study the relationship between circ_CELF1, miR-491-5p, and EGFR. Results: circ_CELF1 is upregulated in primary cancer tissues from patients with NSCLC, and a high level of circ_CELF1, is associated with malignant characteristics and poor outcomes of patients with NSCLC. Enforced expression of circ_CELF1 exacerbated the malignant transformation of NSCLC cells. Mechanistically, through directly interacting with miR-491-5p, circ_CELF1 acted as a miRNA sponge that increased the expression of the miR-491-5p target gene EGFR, eventually promoting the progression of NSCLC and increasing cancer resistance to immunotherapy. Conclusion: Our data demonstrate that upregulation of circ_CELF1 elicits both oncogenic and immunoregulatory effects on the development of NSCLC. We believe that circ_CELF1 can act as a potential therapeutic target for the treatment of NSCLC.
format Online
Article
Text
id pubmed-8660608
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-86606082021-12-13 Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis Ge, Wen Chi, Hao Tang, Hua Xu, Jianjun Wang, Jing Cai, Wan Ma, Haitao Aging (Albany NY) Research Paper Aim: To explore the immunoregulatory effects of circ_CELF1 in non-small cell lung cancer (NSCLC). Methods: The mRNA level of circ_CELF1 in primary tissue samples was analyzed by qRT-PCR. The assays of CCK-8, colony formation, wound healing as well as Transwell were employed for measurement of cancer cell malignant transformation. The murine subcutaneous tumor model was used to assess the tumorigenesis of NSCLC in vivo. The assays of circRNA precipitation, RNA immunoprecipitation, and luciferase reporter were performed to study the relationship between circ_CELF1, miR-491-5p, and EGFR. Results: circ_CELF1 is upregulated in primary cancer tissues from patients with NSCLC, and a high level of circ_CELF1, is associated with malignant characteristics and poor outcomes of patients with NSCLC. Enforced expression of circ_CELF1 exacerbated the malignant transformation of NSCLC cells. Mechanistically, through directly interacting with miR-491-5p, circ_CELF1 acted as a miRNA sponge that increased the expression of the miR-491-5p target gene EGFR, eventually promoting the progression of NSCLC and increasing cancer resistance to immunotherapy. Conclusion: Our data demonstrate that upregulation of circ_CELF1 elicits both oncogenic and immunoregulatory effects on the development of NSCLC. We believe that circ_CELF1 can act as a potential therapeutic target for the treatment of NSCLC. Impact Journals 2021-11-17 /pmc/articles/PMC8660608/ /pubmed/34788230 http://dx.doi.org/10.18632/aging.203576 Text en Copyright: © 2021 Ge et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Ge, Wen
Chi, Hao
Tang, Hua
Xu, Jianjun
Wang, Jing
Cai, Wan
Ma, Haitao
Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title_full Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title_fullStr Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title_full_unstemmed Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title_short Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis
title_sort circular rna celf1 drives immunosuppression and anti-pd1 therapy resistance in non-small cell lung cancer via the mir-491-5p/egfr axis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660608/
https://www.ncbi.nlm.nih.gov/pubmed/34788230
http://dx.doi.org/10.18632/aging.203576
work_keys_str_mv AT gewen circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT chihao circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT tanghua circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT xujianjun circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT wangjing circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT caiwan circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis
AT mahaitao circularrnacelf1drivesimmunosuppressionandantipd1therapyresistanceinnonsmallcelllungcancerviathemir4915pegfraxis